PURPOSE: Animal models of breast cancer metastases that recapitulate the pattern of metastatic progression seen in patients are lacking; metastatic breast cancer models do not currently exist for evaluation of immune-mediated therapies. We have developed and characterized a preclinical model for the evaluation of immune-mediated metastatic breast cancer therapies. EXPERIMENTAL DESIGN: The NT2.5 mammary tumor cell line was injected into the left cardiac ventricle of immunotolerant transgenic neu-N mice and athymic nu/nu mice. Metastatic progression was monitored by bioluminescent, small-animal magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography/computed tomography imaging, and also by histopathology. Antigen expression in normal organs and tumor metastases was evaluated by Western blot analysis and flow cytometry. RESULTS: Left cardiac ventricle injection of NT2.5 cells yielded widespread metastases in bones, liver, and spleen. Three to four weeks after injection, mice exhibited hind limb paralysis and occasional abdominal enlargement. Bioluminescence imaging of metastatic progression was successful in nude mice but the bioluminescent cells were rejected in immunocompetent mice. Other imaging modalities allowed successful imaging of nonbioluminescent cells. Small-animal positron emission tomography imaging allowed visualization of disease, in vivo, in the bones and liver. Magnetic resonance imaging revealed initial dissemination of the tumor cells to the bone marrow. Small-animal single-photon emission computed tomography/computed tomography imaging identified metastatic bone lesions targeted by a radiolabeled antibody. CONCLUSION: The model closely recapitulates the pattern of metastatic spread in breast cancer. This immunotolerant metastatic model is a novel addition to existing breast cancer models and coupling the model with in vivo imaging greatly facilitates the evaluation of targeted immunotherapies of metastasis.
PURPOSE: Animal models of breast cancer metastases that recapitulate the pattern of metastatic progression seen in patients are lacking; metastatic breast cancer models do not currently exist for evaluation of immune-mediated therapies. We have developed and characterized a preclinical model for the evaluation of immune-mediated metastatic breast cancer therapies. EXPERIMENTAL DESIGN: The NT2.5 mammary tumor cell line was injected into the left cardiac ventricle of immunotolerant transgenicneu-N mice and athymic nu/nu mice. Metastatic progression was monitored by bioluminescent, small-animal magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography/computed tomography imaging, and also by histopathology. Antigen expression in normal organs and tumor metastases was evaluated by Western blot analysis and flow cytometry. RESULTS: Left cardiac ventricle injection of NT2.5 cells yielded widespread metastases in bones, liver, and spleen. Three to four weeks after injection, mice exhibited hind limb paralysis and occasional abdominal enlargement. Bioluminescence imaging of metastatic progression was successful in nude mice but the bioluminescent cells were rejected in immunocompetent mice. Other imaging modalities allowed successful imaging of nonbioluminescent cells. Small-animal positron emission tomography imaging allowed visualization of disease, in vivo, in the bones and liver. Magnetic resonance imaging revealed initial dissemination of the tumor cells to the bone marrow. Small-animal single-photon emission computed tomography/computed tomography imaging identified metastatic bone lesions targeted by a radiolabeled antibody. CONCLUSION: The model closely recapitulates the pattern of metastatic spread in breast cancer. This immunotolerant metastatic model is a novel addition to existing breast cancer models and coupling the model with in vivo imaging greatly facilitates the evaluation of targeted immunotherapies of metastasis.
Authors: Gabri van der Pluijm; Ivo Que; Bianca Sijmons; Jeroen T Buijs; Clemens W G M Löwik; Antoinette Wetterwald; George N Thalmann; Socrates E Papapoulos; Marco G Cecchini Journal: Cancer Res Date: 2005-09-01 Impact factor: 12.701
Authors: Andy J Minn; Yibin Kang; Inna Serganova; Gaorav P Gupta; Dilip D Giri; Mikhail Doubrovin; Vladimir Ponomarev; William L Gerald; Ronald Blasberg; Joan Massagué Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: Charlotte Kuperwasser; Scott Dessain; Benjamin E Bierbaum; Dan Garnet; Kara Sperandio; Gregory P Gauvin; Stephen P Naber; Robert A Weinberg; Michael Rosenblatt Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: C T Guy; M A Webster; M Schaller; T J Parsons; R D Cardiff; W J Muller Journal: Proc Natl Acad Sci U S A Date: 1992-11-15 Impact factor: 11.205
Authors: Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Anne M Ercolini; Brian H Ladle; Elizabeth A Manning; Lukas W Pfannenstiel; Todd D Armstrong; Jean-Pascal H Machiels; Joan G Bieler; Leisha A Emens; R Todd Reilly; Elizabeth M Jaffee Journal: J Exp Med Date: 2005-05-09 Impact factor: 14.307
Authors: Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros Journal: Cancer Res Date: 2010-07-22 Impact factor: 12.701
Authors: Hong Song; Mohammad Hedayati; Robert F Hobbs; Chunbo Shao; Frank Bruchertseifer; Alfred Morgenstern; Theodore L Deweese; George Sgouros Journal: Mol Cancer Ther Date: 2013-07-19 Impact factor: 6.261
Authors: Hong Song; Robert F Hobbs; Ravy Vajravelu; David L Huso; Caroline Esaias; Christos Apostolidis; Alfred Morgenstern; George Sgouros Journal: Cancer Res Date: 2009-11-17 Impact factor: 12.701
Authors: Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau Journal: Clin Cancer Res Date: 2019-11-15 Impact factor: 12.531
Authors: Jae-Beom Kim; Konnie Urban; Edward Cochran; Steve Lee; Angel Ang; Bradley Rice; Adam Bata; Kenneth Campbell; Richard Coffee; Alex Gorodinsky; Zhan Lu; He Zhou; Takashi Kei Kishimoto; Peter Lassota Journal: PLoS One Date: 2010-02-23 Impact factor: 3.240
Authors: Anders Josefsson; Jessie R Nedrow; Sunju Park; Sangeeta Ray Banerjee; Andrew Rittenbach; Fabien Jammes; Benjamin Tsui; George Sgouros Journal: Cancer Res Date: 2015-11-10 Impact factor: 12.701
Authors: Diahnn F Campbell; Rebecca Saenz; Ila S Bharati; Daniel Seible; Liangfang Zhang; Sadik Esener; Bradley Messmer; Marie Larsson; Davorka Messmer Journal: Breast Cancer Res Date: 2015-03-31 Impact factor: 6.466